Browse > Article
http://dx.doi.org/10.22643/JRMP.2017.3.2.80

Preclinical application of 188Re-Tin colloid for treatment of mouse tumor model with peritoneal effusion  

Jin, Yong Nan (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
Lee, Yong Jin (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
Kim, Young Joo (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
Lee, Yun-Sang (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
Jeong, Jae Min (Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine)
Publication Information
Journal of Radiopharmaceuticals and Molecular Probes / v.3, no.2, 2017 , pp. 80-84 More about this Journal
Abstract
Re-188 is an excellent and practical radioisotope produced by W-188/Re-188-generator for therapy. We prepared Re-188-tin colloid for therapy of various diseases and tried to treat peritoneal effusion in animal model. Sarcoma-180 cells were injected into ICR mice to induce peritoneal effusion and the mice were grown for 3 d. Re-188-tin colloids (0.25, 0.5, and 1 mCi/mL per 30 g body weight) were injected into the mice and the mice were grown for 90 d. Planar gamma scintigraphy showed even distribution of Re-188-tin colloid radioactivity. Bax expression was found to be dose dependent to Re-188-tin colloid. Normal saline treated group showed the shortest survival time. Among the treated groups, 0.5 mCi dose group showed the longest survival time. In conclusion, Re-188-tin colloid was prepared successfully and showed the feasibility to use as a peritoneal effusion treatment in mice.
Keywords
Re-188-tin colloid; peritoneal effusion; radionuclide therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Parsons SL, Watson SA, Stelle RJC. Malignant ascites. Br J Surg 1996;83: 6-14.   DOI
2 Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large-volume malignant ascites. J Surg Oncol 1996;62:93-96.   DOI
3 Muller JH. Weitere Entwicklung der Therapie von peritoneal-carcinosen bei Ovarialcarcinom mit kunstilicher radioactivitat ($Au-^{198}$). Gynaecologia 1950;129:289-294.
4 Rogoff EE, Romano R, Hahn EW. The prevention of Ehrlich ascites tumor using intraperitoneal colloidal 198Au. Dose vs. size of inoculum. Radiology 1975;114:225-226.   DOI
5 Jacobs ML. Radioactive colloidal chromic phosphate to control pleural effusion of ascites. J Am Med Assoc 1958;166:597-599.   DOI
6 Boye E, Lindegaard MW, Paus E, Skretting A, Davy M, Jakobsen E. Whole-body distribution of radioactivity after intraperitoneal administration of $^{32}P$ colloids. Br J Radiol 1984;57:395-402.   DOI
7 Balink H, Sijmons EA Zonnenberg BA, De Klerk JM. Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites. Clin Nucl Med 2003;28:545-547.   DOI
8 Knapp FF Jr. Rhenium-188 - a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 1998;13: 337-349.   DOI
9 Jeong JM, Chung JK. Therapy with 188Re-labeled raidiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 2003;18:707-717.   DOI
10 Jeong JM, Lee YJ, Kim EH, Chang YS, Kim YJ, Son M, Lee DS, Chung JK, Lee MC. Preparation of (188) Re-labeled Re-labeled paper for treating of skin cancer. Appl Radiat Isot 2003;58:551-555.   DOI
11 Jeong JM, Kim YJ, Lee YS,Ko JI, Son M, Lee DS, Chung JK, Park JH, Lee MC. Lipiodol solution of a lipophilic agent, (188)Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28:197-204.   DOI
12 Lee YS, Jeong JM, Kim YJ, Chung JW, Park JH, Suh YG, Lee DS, Chung JK, Lee MC. Synthesis of 188 Re-labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237-242.   DOI
13 Knapp FF, Callahan AP, Beets AL, Mirzadeh S, Hsieh BT. Processing of reactor-produced $^{188}W$ for fabrication of clinical scale alumina-based $^{188}W$/$^{188}Re$ generators. Appl Radiat Isot 1994;45:1123-1128.   DOI
14 Lee EB, Shin KC, Lee YJ, Cheon GJ, Jeong JM, Son MW, Song YW. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl Med Commun 2003;24:689-696.   DOI
15 Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF Jr, Biersack HJ. Dose escalation study with r rhenium-188hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000;27:123-130.   DOI
16 Croll MN, Brady LW. Intracavitary uses of colloids. Semin Nucl Med 1979;9:108-113.   DOI
17 Lambert B, Bacher K, Defreyne L, Van Vlierberghe H, Jeong JM, Wang RF, van Meerbeeck J, Smeets P, Troisi R, Thierens H, De Vos F, Van de Wiele C. (188)Re- HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344-352.   DOI
18 Savio E, Guadiano J, Robles AM, Balter H, Paolino A, Lopez A, Hermida JC, De Marco E, Martinez G, Osinaga E, Knapp FF Jr. Re-HEDP: Pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 2001;1:2.   DOI
19 Lambert B, Bacher K, Keukeleire KD, Smeets P, Colle I, Jeong JM, Thierens H, Troisi R, De Vos F, Van de Wiele C. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J Nucl Med 2005;46:1326-1332.
20 Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong JM, Dierckx RA, Van de Wiele C, Thierens H, De Vos F. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial.. J Nucl Med 2005; 46:60-66.
21 Wang S-J, Lin W-Y, Hsieh B-T, Shen LH, Tsai ZT, Ting G, Knapp FF Jr. Rhenium-188 sulfur colloid as a radiation synovectomy agent. Eur J Nucl Med 1995;22:505-507.   DOI
22 Jeong JM, Lee YJ, Kim YJ, Chang YS, Lee DS, Chung JK, Song YW, Lee MC. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot 2000;52:851- 855   DOI
23 Chen FD, Hsieh BT, Wang HE, Ou YH, Yang WK, Whang- Peng J, Liu RS, Knapp FF, Ting G, Yen SH. Efficacy of Re-188-labelled sulphur colloid on prolongation of survival time in melanoma-bearing animals. Nucl Med Biol 2001;28:835-844.   DOI
24 Lee EB, Shin KC, Lee YJ, Cheon GJ, Jeong JM, Son MW, Song YW. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl Med Commun 2003;24:689-696.   DOI